BDR Pharma lines up more compulsory licences: Sources

Indian generic drug maker BDR Pharma's plans could draw new battles lines over intellectual property rights. After seeking a compulsory license for leukemia drug sprycel, BDR Pharma is setting its sight on more patent-protected anti-cancer drugs, Reports CNBC-TV18's Archana Shukla.

BDR is not stopping at just one compulsory licence application. Sources say that the company is preparing to file its second license now. This time it is for BMS breast cancer drug Ixempra.

Also read: Ranbaxy awaits USFDA nod for mystery drug on Mar 25

The company is likely to file and submit their application to the patent office by the end of next week. It is believed to be offering a price at 90 percent discount to the current selling price of Ixempra, which is at around Rs 80,000 per vial. This is one of the grounds on which BDR is planning to file the compulsory licence application. This one is an unaffordable cost as well as non-availability of the drug in the Indian market.

Sources also say that the company is also preparing to file another compulsory licence application for Herceptin. Right now there are a lot of regulatory hurdles yet to be cleared in terms of lack of approval pathway for generic biotech drugs. Once those are cleared the company will be filing another one for Herceptin.

Anda sedang membaca artikel tentang

BDR Pharma lines up more compulsory licences: Sources

Dengan url

http://harmonisem.blogspot.com/2013/03/bdr-pharma-lines-up-more-compulsory.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

BDR Pharma lines up more compulsory licences: Sources

namun jangan lupa untuk meletakkan link

BDR Pharma lines up more compulsory licences: Sources

sebagai sumbernya